JAC Advance Access originally published online on January 6, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 51, 339-345
© 2003 The British Society for Antimicrobial Chemotherapy
Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific
1 Department of Microbiology and Infectious Diseases, Women’s and Children’s Hospital, 72 King William Road, North Adelaide, SA 5006, Australia; 2 Buffalo Clinical Research Center, Buffalo, NY; 3 The Jones Group/JMI Laboratories, North Liberty, IA; 4 Tufts University School of Medicine, Boston, MA, USA
Received 28 July 2002; returned 12 September 2002; revised 31 October 2002; accepted 4 November 2002
Multiresistance to antimicrobial agents is common in staphylococci and pneumococci isolates in the Western Pacific region. The activity of linezolid, a new oxazolidinone, was evaluated against a spectrum of Gram-positive species collected in the region. Eighteen laboratories from six countries in the Western Pacific examined the linezolid susceptibility of 2143 clinical isolates of Staphylococcus aureus, coagulase-negative staphylococci (CoNS) and Enterococcus spp. using broth microdilution or disc diffusion methodology. For Streptococcus pneumoniae (n = 351) and other streptococci (n = 83), Etest (AB Biodisk, Solna, Sweden) strips were used. Results were compared with other common and important antimicrobials. Linezolid-resistant strains were not detected among streptococci or staphylococci, including a significant proportion of S. aureus strains that were multiresistant. Almost all enterococci, including 14 vancomycin-resistant Enterococcus faecium, were linezolid susceptible. A small proportion of enterococci (0.8%) were intermediate to linezolid, and one strain of Enterococcus faecalis had a zone diameter of 20 mm (resistant). The linezolid MIC ranges (MIC90) of those strains tested by broth microdilution or Etest were: 1–4 mg/L (2 mg/L) for S. aureus, 0.5–4 mg/L (2 mg/L) for CoNS, 0.5–4 mg/L (2 mg/L) for Enterococcus spp., 0.12–2 mg/L (1 mg/L) for S. pneumoniae and 0.25–2 mg/L (1 mg/L) for Streptococcus spp. There was no difference in linezolid susceptibility between countries or between multiresistant and susceptible strains of each species monitored.
Keywords: linezolid, Western Pacific region, ZAPS
* Corresponding author. Tel: +61-8-8161-6359; Fax: +61-8-8161-6051; E-mail: bellj{at}mail.wch.sa.gov.au
ZAPS Western Pacific Regional Participants are listed in the Acknowledgements.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. N. Jones, M. G. Stilwell, P. A. Hogan, and D. J. Sheehan Activity of Linezolid against 3,251 Strains of Uncommonly Isolated Gram-Positive Organisms: Report from the SENTRY Antimicrobial Surveillance Program Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1491 - 1493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kelly, J. Collins, M. Davin, C. Gowing, and P. G. Murphy Linezolid resistance in coagulase-negative staphylococci1 J. Antimicrob. Chemother., October 1, 2006; 58(4): 898 - 899. [Full Text] [PDF]
|
|
|
|
|
|
R. N. Jones, J. E. Ross, T. R. Fritsche, and H. S. Sader Oxazolidinone susceptibility patterns in 2004: report from the Zyvox(R) Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations J. Antimicrob. Chemother., February 1, 2006; 57(2): 279 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Phillips, M. Casewell, T. Cox, B. De Groot, C. Friis, R. Jones, C. Nightingale, R. Preston, and J. Waddell Antibiotic use in animals J. Antimicrob. Chemother., May 1, 2004; 53(5): 885 - 885. [Full Text] [PDF]
|
|